Mobile

An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen A...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-006055-39

An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate efficacy of degarelix in achieving and maintaining testosterone suppression at castrate levels (≤0.5 ng/mL) during one year of treatment in prostate cancer patients.

Critère d'inclusion

  • Prostate cancer

Liens